Zhejiang Huahai Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company specializing in the production and distribution of formulations, active pharmaceutical ingredients, and intermediates. They are known for their pril products such as captopril, enalapril, and lisinopril. With a high-risk rating score of 39.9, Zhejiang Huahai Pharmaceutical Co., Ltd. is committed to upholding ESG principles in their operations.